Abstract
Overview
Introduction
Although there are many marketed treatments for overactive bladder, there are
few available for stress urinary incontinence or interstitial cystitis.
Furthermore, despite available treatments for overactive bladder, many are
associated with side effects leading to poor treatment compliance. With
significant unmet needs remaining in these markets, there are clear
opportunities for new entrants.
Scope
- Overview of epidemiology, presentation and referral patterns, and
diagnostic assessment for UUI, SUI, MUI, dry OAB, and IC
- Role and use of non-pharmacological versus pharmacological treatment for
UUI, SUI, MUI, dry OAB, and IC
- Influences on treatment choice and perception of current drug therapies
including tolterodine, oxybutynin, darifenacin, solifenacin and duloxetine
- Evaluation of unmet needs and future outlook including awareness of the
R&D drug pipeline
Report Highlights
Drug therapy for urinary disorders has predominantly focused on the overactive
bladder market - particularly urge urinary incontinence (UUI). However, as the
UUI market becomes increasingly crowded, product differentiation is key. By
focusing on the urgency and frequency symptoms, companies may be able to tap
into an under-served market niche.
Stress urinary incontinence (SUI) is considered the most common subtype of
urinary incontinence, but poor awareness and limited treatment options have
impacted presentation, diagnosis and treatment rates. The recent approval of
duloxetine in the EU presents physicians with a much-needed treatment
alternative, but uptake has been slow.
Poor understanding of the underlying causes of interstitial cystitis (IC) have
made diagnosis, management and development of effective drugs for this
disorder difficult. With many physicians resorting to treatments that are not
specifically approved for IC, experts in the field believe that this could be
leading to suboptimal treatment outcomes.
Reasons to Purchase
- Forecast product sales by understanding key aspects of epidemiology,
diagnosis and treatment
- Gain a better understanding of the challenges facing current and future
players in the overactive bladder and urinary incontinence market
- Identify physicians' key concerns including unmet needs and the attributes
that physicians believe are desirable for future treatments
| 
View Cart
